NCT03798717

Brief Summary

Type 2 diabetes mellitus (T2DM) is characterised by chronic high blood sugar concentration (hyperglycaemia) and insulin resistance leading to a reduction in insulin sensitivity. These hyperglycaemic excursions can seriously impact metabolic, micro and macrovascular health. The total cost of the direct and indirect care of individuals with diabetes (\~90% T2DM) in the UK (United Kingdom) is £23.7 billion, equating to \~20% of the annual national health service (NHS) budget, with this projected to become unsustainable. Low-cost interventions to improve glycaemic control in these individuals are therefore warranted. Current interventions include pharmaceuticals, exercise and calorie restrictive diets. Pharmaceutical interventions carry a high financial cost, while exercise and diet programmes have a low adherence rate in individuals with T2DM. Heat therapy offers one potential low cost therapy. Immersion in a hot tub for 30 mins.day-1 for 10 days has been shown to reduce fasting plasma \[glucose\] and HbA1c in individuals with T2DM, which may be explained by acute (e.g. muscle) and chronic (e.g. reduced inflammatory status and increased heat shock proteins (HSP)) adaptations, although experimental evidence for these hypothesis are sparse. Other potential benefits include improved glycaemic control, insulin sensitivity, elevated resting metabolic rate and improved micro- and macrovascular function. The aim of the present study is to determine whether acute hot water immersion can improve glucose tolerance in individuals with T2DM and whether it is more beneficial to undertake this before or after a OGTT (oral glucose tolerance test).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Feb 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 20, 2018

Completed
21 days until next milestone

First Posted

Study publicly available on registry

January 10, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

February 20, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 9, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 9, 2020

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

July 19, 2021

Completed
Last Updated

July 21, 2021

Status Verified

July 1, 2021

Enrollment Period

1 year

First QC Date

December 20, 2018

Results QC Date

April 29, 2021

Last Update Submit

July 19, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean AUC (Area Under the Curve) Plasma [Glucose]

    Does an acute bout of passive, warm water therapy reduce plasma \[glucose\]? Units for AUC are AU (arbitrary units) which have been derived from the trapezoidal method and have been published as such. Trapezoidal method: AUC = Δx ((y0/2)+y1+y2+y3+...+(yn/2)).

    Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks

Secondary Outcomes (6)

  • Change in Plasma [Insulin]

    Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks

  • Mean Insulin Sensitivity

    Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks

  • Change in Fuel Utilisation

    Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks

  • Change in Cardiovascular Status

    Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks

  • Change in eHSP70 (Extracellular Heat Shock Protein 70)

    Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks

  • +1 more secondary outcomes

Study Arms (3)

Control

NO INTERVENTION

Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (\~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.

Pre OGTT

EXPERIMENTAL

Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (\~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.

Diagnostic Test: Heating

Post OGTT

EXPERIMENTAL

Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.

Diagnostic Test: Heating

Interventions

HeatingDIAGNOSTIC_TEST

Warm water immersion

Also known as: Bath
Post OGTTPre OGTT

Eligibility Criteria

Age35 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • The participant may not enter / be withdrawn from the study if any of the following apply:
  • Severe peripheral neuropathy (to the point to which they cannot sense temperature)
  • Uncontrolled hypertension (≥180 systolic / 100 diastolic mmHg)
  • Taking any medication which may interfere with data interpretation or safety
  • Who have had a myocardial infarction or cerebro-vascular event
  • Any cardiac abnormalities which restrict hard exercise
  • Current smokers or who have stopped within 3 months
  • Participant is unable to understand and/or fully cooperate with the study protocol
  • Any other serious medical condition which would interfere with data interpretation or safety will be excluded from participation.
  • Any skin conditions including ulcerations

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Sport and Exercise Science

Portsmouth, Hampshire, PO1 2ER, United Kingdom

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Results Point of Contact

Title
Dr. Ant Shepherd
Organization
University of Portsmouth

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Lecturer

Study Record Dates

First Submitted

December 20, 2018

First Posted

January 10, 2019

Study Start

February 20, 2019

Primary Completion

March 9, 2020

Study Completion

March 9, 2020

Last Updated

July 21, 2021

Results First Posted

July 19, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

There is no plan to release IPD (individual patient data), until all avenues of further funding have been exhausted.

Locations